MARÍA CALLEJO ARRANZ-rekin lankidetzan egindako argitalpenak (11)

2024

  1. Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human

    Vascular Pharmacology, Vol. 155

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  3. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

2022

  1. Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats

    American journal of respiratory cell and molecular biology

2021

  1. Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension

    Antioxidants, Vol. 10, Núm. 2, pp. 1-14

  2. Restoration of vitamin d levels improves endothelial function and increases task-like k+ currents in pulmonary arterial hypertension associated with vitamin d deficiency

    Biomolecules, Vol. 11, Núm. 6

  3. Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension

    European Respiratory Journal

2020

  1. Total, bioavailable, and free vitamin D levels and their prognostic value in pulmonary arterial hypertension

    Journal of Clinical Medicine, Vol. 9, Núm. 2

2019

  1. Impact of vitamin D deficit on the rat gut microbiome

    Nutrients, Vol. 11, Núm. 11

  2. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries

    Journal of Physiology, Vol. 597, Núm. 4, pp. 1185-1197